Anti–Vascular Endothelial Growth Factor Bevacizumab (Avastin) for Radiation Retinopathy

Objective

To evaluate intravitreal bevacizumab for radiation retinopathy.

Methods

After plaque radiation therapy, 6 patients developed radiation retinopathy (retinal edema, hemorrhages, microangiopathy, and neovascularization). Intravitreal bevacizumab (1.25 mg in 0.05 mL) was periodically injected (every 6-8 weeks). Ophthalmic evaluations included visual acuity, ophthalmic examination, fundus photography, fluorescein...